Platinum agent-induced hypersensitivity reactions: Data mining of the public version of the FDA adverse event reporting system, AERS

International Journal of Medical Sciences

Volumn 8, Issue 4, 2011, Pages 332-338

  Sakaeda, Toshiyuki ^a   Kadoyama, Kaori ^a   Yabuuchi, Hiroaki ^a,b   Niijima, Satoshi ^a   Seki, Kyoko ^c   Shiraishi, Yukinari ^c   Okuno, Yasushi ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b Kyoto Constella Technologies Co Ltd   (Japan)

^c KOBE ROSAI HOSPITAL   (Japan)

Author keywords

Adverse event; AERS; Hypersensitivity; Platinum agent

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; OXALIPLATIN;

ARTIFICIAL NEURAL NETWORK; BAYES THEOREM; DATA MINING; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; REVIEW; SIGNAL DETECTION;

EID: 79958779443     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8.332     Document Type: Review

References (39)

1. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355: 1041-1047.
2. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 2004; 22: 229-237.
3. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18: 2938-2947.
4. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22: 23-30.
5. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004; 22: 1209-1214.
6. Venook A. Critical evaluation of current treatments in meta-static colorectal cancer. Oncologist. 2005; 10: 250-261.
7. Lee JJ, Chu E. An update on treatment advances for the first-line therapy of metastatic colorectal cancer. Cancer J. 2007; 13: 276-281.
8. Sabharwal A, Kerr D. Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future. Expert Rev Anticancer Ther. 2007; 7: 477-487.
9. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol. 2003; 24: 253-262.
10. Heywood GR, Rosenberg SA, Weber JS, et al. Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2. J Natl Cancer Inst. 1995; 87: 915-922.
11. Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999; 17: 1141-1145.
12. Markman M. Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf. 2003; 2: 597-607.
13. Syrigou E, Syrigos K, Saif MW. Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep. 2008; 8: 56-62
14. Eng C. Toxic effects and their management: daily clinical chal-lenges in the treatment of colorectal cancer. Nat Rev Clin Oncol. 2009; 6: 207-218.
15. Makrilia N, Syrigou E, Kaklamanos I, et al. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs 2010; 2010: 207084.
16. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and manage-ment of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol. 2009; 102: 179-187.
17. Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter inter-national study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators, oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350: 2343-2351.
18. Thomas RR, Quinn MG, Schuler B, et al. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2003; 97: 2301-2307.
19. Siu SW, Chan RT, Au GK, et al. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol. 2006; 17: 259-261.
20. Maindrault-Goebel F, Andre T, Tournigand C, et al. Aller-gic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 2005; 41: 2262-2267.
21. Gowda A, Goel R, Berdzik J, et al. Hypersensitivity reactions to oxaliplatin: incidence and management. Oncology. 2004; 18: 1671-1675.
22. Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity reac-tions related to oxaliplatin (OHP). Br J Cancer. 2003; 89: 477-481.
23. Shibata Y, Ariyama H, Baba E, et al. Oxaliplatin-induced aller-gic reaction in patients with colorectal cancer in Japan. Int J Clin Oncol. 2009; 14: 397-401.
24. Seki K, Senzaki K, Tsuduki Y, et al. Multicenter trial on hyper-sensitivity reactions following treatment with FOLFOX regi-mens. Jpn J Pharm Health Care Sci. 2008; 34: 919-926.
25. Seki K, Senzaki K, Tsuduki Y, et al. Risk factors for oxali-platin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci. 2010; 8: 210-215.
26. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, et al. The safety of rosuvastatin as used in common clinical practice: a postmar-keting analysis. Circulation. 2005; 111: 3051-3057.
27. Zipes DP, Zvaifler NJ, Glassock RJ, et al. Rosuvastatin: an in-dependent analysis of risks and benefits. MedGenMed. 2006; 8: 73.
28. Holoshitz N, Alsheikh-Ali AA, Karas RH. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. Am J Cardiol. 2008; 101: 95-97.
29. Colman E, Szarfman A, Wyeth J, et al. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins de-tected in FDA's spontaneous adverse event reporting system. Pharmacoepidemiol Drug Saf. 2008; 17: 1068-1076.
30. Bottone FGJr, Barry WT. Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002. Curr Med Res Opin. 2009; 25: 1535-1550.
31. Clark JA, Humphries JE, Crean S, et al. Topical bovine throm-bin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Report-ing System. Pharmacoepidemiol Drug Saf. 2010; 19: 107-114.
32. Hansen RA, Gartlehner G, Powell GE, et al. Serious adverse events with infliximab: analysis of spontaneously reported ad-verse events. Clin Gastroenterol Hepatol. 2007; 5: 729-735.
33. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001; 10: 483-486
34. van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spon-taneous reporting systems for adverse drug reactions. Phar-macoepidemiol Drug Saf. 2002; 11: 3-10.
35. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998; 54: 315-321.
36. Szarfman A, Machado SG, O'Neill RT. Use of screening algo-rithms and computer systems to efficiently signal high-er-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 2002; 25: 381-392.
37. Bate A, Evans SJ. Quantitative signal detection using sponta-neous ADR reporting. Pharmacoepidemiol Drug Saf. 2009; 18: 427-436.
38. Gould AL. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf. 2003; 12: 559-574.
39. Almenoff JS, Pattishall EN, Gibbs TG, et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin Phar-macol Ther. 2007; 82:157-166.